Last week Venable scored an important victory in federal court on behalf of Ranbaxy in the first test of what limits may be placed on reverse payment deals among drugmakers to protect steady streams of revenue on popular drugs. The case against AstraZeneca and Ranbaxy challenged a 2008 settlement of a patent lawsuit that stalled sales of a cheaper version of Nexium in the U.S. until AstraZeneca's patents expired last May. The case is the first reverse payment antitrust suit to go to trial since the U.S. Supreme Court ruled in June 2013 that the Hatch-Waxman Act settlements could be challenged under federal antitrust law.
The Venable trial team was led by Doug Baldridge and included partners Lisa Jose Fales
, Danielle R. Foley
, associates Vincent Verrocchio
, Paul Feinstein
, Sarah Choi and Molly Cusson with Marta Markowska and Jeanne Mooney.
On December 11, 2014, the Wall Street Journal
continued their coverage of the landmark victory with Law360 noting it in its "Legal Lions" column of top wins over the past week.